A viewer on my Livestream Friday brought to my attention that Pfizer NYSE:PFE is coming off a major low (COVID Low) and has done a pullback to the 50% of the Impulse Move off said low. This is why I love doing Livestreams and having a trading community... idea crowdsourcing! I like these setups especially as the S&P 500 and many stocks within it are making new...
The launch of a Bitcoin ETF could have a significant impact on Coinbase, the largest cryptocurrency exchange in the United States. Some analysts believe that the ETF could lead to a decline in trading volume on Coinbase, as investors may choose to trade Bitcoin through the ETF rather than directly on the exchange. Additionally, the ETF could put pressure on...
In a significant stride towards enhancing public health, Health Canada has recently granted approval for Pfizer's groundbreaking bivalent Respiratory Syncytial Virus (RSV) vaccine, ABRYSVO™. This development is a crucial step in safeguarding both older adults and infants through maternal immunization. With the potential to revolutionize preventive healthcare,...
Moderna has had an astronomical rise due to the vaccine. The technical setup looks excellent to the short side. TD9's on the daily, 2 day, 3 day, big divergences on many timeframes. That said - there is headline risk with this - if they get FDA approval it would likely squeeze.
As a double top a lot of thinks in my mind. i will update ...
Pfizer is one of those companies that we all feel has been shady and the stock value shows it. As much as human emotion can draw this value down, hedge funds and smart money will start stepping in now. The chart says it all. We are talking about one of the longest running publically traded companies folks, this will rebound. Its not a matter of if, but when. I...
Key Takeaway 1. Shares of Pfizer tanked Wednesday as investors digested the subpar guidance, falling as much as 9% to below $26 in morning trading, hitting their lowest intraday share price since 2013. That’s the largest single-day drop for Pfizer since January 2009. 2. Pfizer said Wednesday it expects 2024 revenue to come in between $58.5 billion and $61.5...
Pfizer will retool its obesity drug efforts, but the delay is a blow to the group's ambitions to challenge Novo Nordisk and Lilly in the fast-developing space. Pfizer (NYSE: PFE) - shares slumped Friday after the drugmaker said it would not advance a study of its two-dose obesity treatment, following a high level of side effects in patients involved in the Phase...
PFIZER - Weekly - TIME TO BUY? These are my keylevels on weekly time frame , the price its almost on monthly support where i will add some aditional shares on my portfolio
H i, I looked at Pfizer's chart and it looks like this deep correction won't stop until the $30 zone. The fact that side effects have developed worldwide due to the Covid vaccine and many people have filed lawsuits against pharmaceutical companies probably also plays a role in this deep decline. There is a lot of money in the pharmaceutical industry, so I think...
Analyzing the options chain and the chart patterns of PFE Pfizer prior to the earnings report this week, I would consider purchasing the 30usd strike price at the money Calls with an expiration date of 2023-11-10, for a premium of approximately $0.91. If these options prove to be profitable prior to the earnings release, I would sell at least half of...
Pfizer PFE announced that the FDA has granted approval to its oral, once-daily pill called etrasimod to treat moderately-to-severely active ulcerative colitis (UC). The oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator will be marketed by the brand name of Velsipity (2 mg dose). The approval for etrasimod was based on data from two...
Pfizer's Stock: Is it Worth the Investment Amidst Challenges and Opportunities? Pfizer, a pharmaceutical powerhouse, has made headlines in recent years, primarily for its groundbreaking coronavirus vaccine. Despite achieving over $100 billion in annual revenue last year, the company's stock has witnessed a significant decline of approximately 35% in the current...
Pfizer (PFE) has been trading within a Channel Down pattern since the start of the year and on Friday it registered the strongest green 1D candle since the recent Lower Low leg started in August. This is technically the start of the new rebound leg towards a new Lower High. Those have been priced within the 1D MA50 (blue trend-line) and 1D MA100 (green...
My name is Philip, I am a German swing-trader with 4+ years of trading experience and I only trade stocks , crypto , options and indices 🖥️ I only focus on the higher timeframes because this allows me to massively capitalize on the major market swings and cycles without getting caught up in the short term noise. This is how you build real long term...
Hello Traders Investors And Community, welcome to this analysis where we are looking at the 4-hour timeframe perspective of stock value PFIZER, the recent events, the current formation structure, what needs to be fulfilled that the stock confirms properly and what are possible trading opportunities when the stock has confirmed. As the main stock-market has...
Here's not much on the chart. But what you see is evident. The pitchforks median line is respected by price many times. And this time it's the same. But there's a reason why this time price could flush down to the L-MLH. Indexes are weaker and weaker. The first profit target for me is either the L-MLH, or the A/R (yellow) line. The Action/Reaction line is...
On the monthly chart, Pfizer looks to continue it's push upwards towards higher highs as it currently is losing downwards momentum illustrated by the bullish RSI divergences while it gets closer towards the bottom prices channel support as well as the volume profile point of control. COVID 2.0 incoming?